A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague

Two doses of the vaccine provided complete protection against both inhalational anthrax and pneumonic plague in animal models. Further, results establish the T4 nanoparticle as a novel platform to develop multivalent vaccines against pathogens of high public health significance.

CEPI Awards Contract Worth Up To $19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced a collaboration to advance the development and manufacture of a vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) along with preclinical development of novel vaccines against Lassa and Nipah viruses.

Synthetic DNA Vaccine Effective Against Influenza A Virus Subtype That Is Responsible for More Severe Influenza Seasons

Currently available vaccines for the prevention of seasonal influenza virus infection have limited ability to induce immunity against diverse H3N2 viruses, an influenza A subtype that has led to high morbidity and mortality in recent years.